Is INSM a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

509 people get INSM articles and Market Currents by email alert.

Get email alerts on INSM »

HEADLINES:

2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play
Scott Matusow • Wed, May 15 • 10 Comments
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe

Marketwire (Tue, 8:00AM)
Insmed to Present at the UBS Global Healthcare Conference

Marketwire (Mon, 8:00AM)
Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Marketwire (May 10, 2013)
Insmed's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
Insmed Reports First Quarter Financial Results

Marketwire (May 7, 2013)
Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013

Marketwire (May 1, 2013)
Quickly Approaching Biopharma Catalyst Events
Scott Matusow • Wed, Apr 24 • 22 Comments
Insmed to Present at the 12th Annual Needham Healthcare Conference

Marketwire (Apr 18, 2013)
Insmed Appoints Matthew Pauls as Chief Commercial Officer

Marketwire (Apr 1, 2013)
ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria

Marketwire (Mar 28, 2013)
Insmed to Present at Future Leaders in the Biotech Industry Conference

Marketwire (Mar 27, 2013)
Insmed Incorporated Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Mar 18 • 2 Comments
Insmed Reports Fourth Quarter and Full Year 2012 Financial Results

Marketwire (Mar 18, 2013)
Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013

Marketwire (Mar 11, 2013)
Insmed to Present at Two Upcoming Investor Conferences

Marketwire (Feb 26, 2013)
8 Biotech Growth Names: Greg Wade
Life Sciences Report • Fri, Feb 8 • 3 Comments
Insmed to Present at Two Upcoming Healthcare Investor Conferences

Marketwire (Feb 6, 2013)
Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference

PR Newswire (Dec 13, 2012)

To learn more about Seeking Alpha Pro, click here.

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • Tue, May 14 • 12 Comments
Insmed, The Definition of Risk
Saj Karsan • Wed, Aug 3, 2011
Insmed Year End, 2009 Update
Jae Jun • Thu, Mar 18, 2010 • 1 Comment
Under the Radar Developments at Insmed
Jae Jun • Sun, Jan 31, 2010 • 8 Comments
Insmed Still Looks Very Undervalued
Jae Jun • Mon, Nov 9, 2009 • 10 Comments
Insmed Is Well Positioned to Make a Good Deal
Jae Jun • Mon, Sep 28, 2009 • 9 Comments
Insmed's Monday Morning Press Release: Reading Between the Lines
VFC's Stock House • Tue, Jul 28, 2009 • 3 Comments
Attention Outraged Insmed Investors: Today Is a New Trading Day
VFC's Stock House • Fri, Jun 26, 2009 • 1 Comment
Insmed Stock Rising on High Volume, But Still a Good Buy
VFC's Stock House • Mon, Jun 8, 2009 • 5 Comments
Will Insmed's IPLEX Meet Expectations?
VFC's Stock House • Mon, May 18, 2009 • 3 Comments

2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play
Scott Matusow • Wed, May 15 • 10 Comments
Quickly Approaching Biopharma Catalyst Events
Scott Matusow • Wed, Apr 24 • 22 Comments
8 Biotech Growth Names: Greg Wade
Life Sciences Report • Fri, Feb 8 • 3 Comments
The Best Stocks I See In The Market (Part 1)
FAF Research • Thu, Nov 8, 2012
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts During The Next 4 - 12 Months
Markus Aarnio • Tue, Aug 21, 2012 • 8 Comments
What's Driving Stocks Tuesday: ECB And Fed Hope And Fumes
Markos Kaminis • Tue, Aug 7, 2012 • 3 Comments
Notable Micro Cap Insider Buys This Week
Gutone • Sun, Jun 24, 2012 • 1 Comment
The Race To Cure Cystic Fibrosis
Peter Geschek • Tue, Jun 12, 2012 • 4 Comments
Notable Micro Cap Insider Buys Last Week
Gutone • Sat, Jun 9, 2012 • 4 Comments
2012's Price To Book Bargains
Value Research • Mon, Jan 9, 2012 • 2 Comments
20 Biotech Stocks That Hedge Funds Are Selling
Kapitall • Sun, Dec 11, 2011 • 1 Comment
11 Biotech Stocks With Bullish Short Trends
Kapitall • Wed, Nov 23, 2011
November's Low Price To Book Stocks Vs. Bankruptcy Risks
Value Research • Fri, Nov 4, 2011 • 3 Comments
BMS Drug Deemed Too Costly: Weekly Round-Up Of Biotech Failures And Mishaps
The Burrill Report • Sun, Oct 16, 2011
Buy And Sell Ideas Based On Monday's Big Biotech News Movers
GuruFundPicks • Tue, Oct 11, 2011
12 Oversold Biotech Stocks Being Bought Up By Smart Money
Kapitall • Wed, Sep 14, 2011
5 Stocks Posting Big Moves Last Week
Alex Shadunsky • Mon, Aug 8, 2011
Stocks to Watch This Week as Market Momentum Wanes
Scott's Investments • Mon, Jun 13, 2011 • 4 Comments
6 Stocks With New Uptrends
Rougemont • Thu, May 26, 2011 • 1 Comment
7 Cheap Stocks With Fresh Insider Buying
Rougemont • Mon, Apr 18, 2011 • 3 Comments

Insmed's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
Insmed Incorporated Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Mar 18 • 2 Comments
Insmed's CEO Presents at Lazard Capital Markets Healthcare Conference (Transcript)
Wed, Nov 14, 2012 • 3 Comments
Insmed Incorporated Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
Insmed's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012
Insmed Incorporated Q2 2008 Earnings Call Transcript
Fri, Aug 8, 2008

Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe

Marketwire (Tue, 8:00AM)
Insmed to Present at the UBS Global Healthcare Conference

Marketwire (Mon, 8:00AM)
Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Marketwire (May 10, 2013)
Insmed Reports First Quarter Financial Results

Marketwire (May 7, 2013)
Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013

Marketwire (May 1, 2013)
Insmed to Present at the 12th Annual Needham Healthcare Conference

Marketwire (Apr 18, 2013)
Insmed Appoints Matthew Pauls as Chief Commercial Officer

Marketwire (Apr 1, 2013)
ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria

Marketwire (Mar 28, 2013)
Insmed to Present at Future Leaders in the Biotech Industry Conference

Marketwire (Mar 27, 2013)
Insmed Reports Fourth Quarter and Full Year 2012 Financial Results

Marketwire (Mar 18, 2013)
Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013

Marketwire (Mar 11, 2013)
Insmed to Present at Two Upcoming Investor Conferences

Marketwire (Feb 26, 2013)
Insmed to Present at Two Upcoming Healthcare Investor Conferences

Marketwire (Feb 6, 2013)
Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference

PR Newswire (Dec 13, 2012)
Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment

PR Newswire (Nov 13, 2012)
Insmed To Present At Two Upcoming Investor Conferences

PR Newswire (Nov 12, 2012)
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012

PR Newswire (Nov 7, 2012)
Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer

PR Newswire (Nov 7, 2012)
Insmed to Host 2012 Third Quarter Earnings Conference Call

PR Newswire (Oct 24, 2012)
Insmed Announces Pricing of Approximately $26 Million Direct Public Offering

PR Newswire (Sep 28, 2012)

INSM vs. ETF Alternatives

Company Description

Insmed Incorporated is a development-stage biopharmaceutical company dedicated to improving the lives of patients battling serious orphan lung diseases through the development and commercialization of novel, targeted inhalation therapies in orphan patient populations with critical unmet needs.... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 12:45 PM Midday top 10 gainers: MFLR +64%. CHCI +33%. NYNY +24%. GPRC +24%. EVK +22%. DVR +21%. DQ +19%. GBR +19%. MRIN +17%. INSM +17%.
Midday top 10 losers: HOTR -16%. XONE -12%. CALI -11%. CSC -10%. UAMY -10%. PRMW -10%. IIJI -9%. ANV -9%. OCLS -9%. CHLN -9%. 1 Comment [On the Move]
Wednesday, May 15, 11:43 AM Insmed (INSM +20%) soars today on the back of an enthusiastic investor response to its lead drug Arikace. Lazard joins the lovefest, initiating the shares with a Buy and an aggressive $ 21 price target. The firm says it expects positive results for Phase 3 and Phase 2b studies for for the drug, with the potential for treating a host of maladies. Additionally, its once-daily dose regimen is convenient for patients, which will make it even more competitive. Lazard thinks revenue from Arikace could top $600M by 2020. Comment! [Healthcare, On the Move]
Tuesday, May 14, 10:23 AM Shares of Insmed (INSM +3.6%) pop after the company says the European Patent Office will grant a patent on ARIKACE, the company's clinical stage, inhaled treatment for cystic fibrosis patients with lung infections. In an exhaustive rundown, SA contributor Scott Matusow claims the drug is a superior alternative to Novartis' (NVS) TOBI for a number of reasons and also says INSM could capture a significant portion of the $424M (annually) market for CF pseudomonas lung infection treatments if top-line Phase III results (due mid-year) show promise. Comment! [Healthcare, On the Move, Quick Ideas]
Tuesday, May 7, 8:18 AM Insmed (INSM): Q1 EPS of -$0.43 beats by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
Sunday, April 14, 10:43 PM The rest of the top 25 June additions to the Russell 2000 expected by Credit Suisse: GNMK, AVIV, FBC, TTS, UNXL, GARS, REMY, BNCN, CBK, VRNG, LFVN, GTN, NLS, ENT, AMRI, POWR, DCO, INSM, CUTR, PPBI. "Very few of the bigger adds are owned by actively managed small cap funds," notes CS. Comment! [Quick Ideas]
Thursday, March 28, 12:23 PM Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an inhaler for treating infections caused by non-tuberculous mycobacteria. The company notes that there's currently no FDA-approved treatment for this particular NTM lung infection. Comment! [Healthcare, On the Move]
Monday, March 18, 7:47 AM Insmed (INSM): Q4 EPS of -$0.49 misses by $0.16. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, November 7, 2012, 7:20 AM Insmed (INSM): Q3 EPS of -$0.38 beats by $0.04. (PR) Comment! [Earnings, Healthcare]
Friday, September 28, 2012, 12:46 PM Insmed (INSM +9.8%) jumps after pricing its direct public offering of approximately 6.3M shares to certain affiliates of Ayer Capital, RA Capital and Quaker Partners, at a price of $4.07 per share, whichs is at par with yesterday's closing price, and indicates strong demand for the shares. The company also disclosed that it expects to offer an additional $2M shares to another investor, which is expected to come on or before October 31. Comment! [On the Move, Healthcare]
Monday, May 7, 2012, 8:37 AM Insmed (INSM) +48.1% premarket after announcing the FDA lifted its clinical hold on INSM's Arikace drug for lung infections in cystic fibrosis patients. Comment! [Healthcare, On the Move]
Friday, January 20, 2012, 9:15 AM Premarket gainers: INSM +24%. ASIA +16%. SWKS +6%. URRE +6%. MPC +5%. BCS +4%. CTIC +4%. RBS +3%. IBM +3%. SAVE +3%. MSFT +3%.
Losers: ALTH -20%. GOOG -8%. AONE -7%. SQNM -6%. HTGC -6%. COF -6%. PH -5%. ZIOP -5%. MMLP -5%. BWP -4%. CX -4%. CUK -4%. ARCC -4%. CCL -3%. NVS -3%. MT -3%. Comment! [On the Move]
Friday, January 20, 2012, 8:49 AM Insmed (INSM) +26.3% after announcing the FDA has lifted the clinical hold previously placed on the company's Arikace drug for treating lung infections. The company says it continues discussions with the FDA on the remaining hold on the drug in the treatment of cystic fibrosis patients. Comment! [Healthcare, On the Move]
Monday, October 10, 2011, 4:27 PM Shares of biotech researcher Insmed (INSM -30%) were hammered today after the FDA notified the company that it is continuing the clinical hold previously placed on phase 3 trials for its cystic fibrosis drug Arikace, a treatment for patients with pseudomonas lung infections. The agency says it still doesn't have sufficient data on the associated risks. Comment! [Healthcare, On the Move]
Monday, October 10, 2011, 9:30 AM Insmed (INSM) drops 32.2% after announcing the FDA is maintaining the clinical hold it placed in August on Phase 3 trials of the company's Arikace drug for treating lung infections. The FDA has requested Insmed conduct an additional study to determine Arikace's toxicity. Comment! [Healthcare, On the Move]
Friday, September 16, 2011, 3:07 PM Insmed (INSM), whose shares collapsed in August on bad regulatory news, is up 10.7% after Wedbush starts coverage with an Outperform and $15 PT. The firm thinks the FDA will lift the clinical hold it's placed on studies of Insmed's Arikace drug in late September or early October, and that the drug can address a $300M opportunity. Comment! [Healthcare, On the Move, Quick Ideas]
Tuesday, August 2, 2011, 9:28 AM Insmed (INSM) is down 40.5% premarket after announcing the FDA has placed a clinical hold on the company's phase 3 clinical trials for its Arikace drug for treating lung illnesses. The FDA has requested additional information on Arikace, which Insmed expects to provide in the next 30 days. Comment! [Healthcare, On the Move]

Scott Matusow
My new article is out now at http://seekingalpha.com/a/uood $INSM is my pick
Tue, 10:02 AM
Reply (2)

• !Report Abuse
View all 2 replies
Rhysode: Nice call Scott
Wed, 12:13 PM
• !Report Abuse
Scott Matusow: thanks
Wed, 1:36 PM
• !Report Abuse
Add a reply...

140 characters

greenbackers
observe INSM rebound at 3.22....recent debacle to upper 2s..trdg well below cash
10/11/11
Reply (1)

• !Report Abuse
View all 1 replies
eyalmy: looks like a solid bottom for INSM
11/3/11
• !Report Abuse
Add a reply...

140 characters

Justin M. Hall
INCY, ZGNX, INSM, COV, NDZ, MRK => Notable Developments and Results 12/2/10 => Rx Investors.com => http://bit.ly/haFLnm
12/2/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Alex B. Gray
Insmed $INSM reported Q3 2010 revenues of $1.8M vs. $2.5M and a net loss of $0.3M vs. a net loss of $0.1M in 2009.
11/3/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tahoe00
INSM trading at 1.01 biotech co. Has 120m in cash. Solid pipeline. Earning on Thursday.Watch and review 10k
5/5/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

joebeckman07
Advice to INSM - Insmed making an impression on Merck,,, mentioned during JP morgan conference in January. http://tinyurl.com/ycnkm9q
1/31/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

joebeckman07
Advice to INSM - Buy Great potential with oncology, Iplex, and the cash to move forward. Excellent history of execution by management.
1/31/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Top Textrader
Two long candidates on radar screen for tomorrow a.m. ---- SMN and INSM. Will follow up in a.m.
1/11/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ari5000
made a killing on CSGH. buying lots of INSM. It's going to run to regain Naz compliance. Will be over 1 soon for sure, if not more.
9/29/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

greenbackers
observe INSM rebound at 3.22....recent debacle to upper 2s..trdg well below cash
10/11/11
Reply (1)

• !Report Abuse
View all 1 replies
eyalmy: looks like a solid bottom for INSM
11/3/11
• !Report Abuse
Add a reply...

140 characters

INSM Insmed, Inc.

INSM

Insmed, Inc.